Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Notal Vision Names Jim Long as Chief Financial Officer

Notal Vision
Posted on: 25 Jul 17

MANASSAS, Va., July 24, 2017 /PRNewswire/ -- Notal Vision, Ltd., a privately-held ophthalmic company that developed and introduced ForeseeHome®, the first FDA-cleared home-based monitoring system for patients with age-related macular degeneration (AMD), today announced the appointment of Jim Long, MBA, as Chief Financial Officer. Mr. Long, who will be responsible for Notal Vision's financial operations and strategy, will report to Quinton Oswald, Chief Executive Officer of Notal Vision.

"Jim is a savvy, strategic finance executive with broad operations and technology expertise. He has a long track record of success with growing private-equity-backed companies where he was instrumental in providing the finance vision, strategy and leadership needed to help these organizations expand," Quinton Oswald, CEO, Notal Vision, said. "With Jim in place, I'm confident we will be well-positioned to meet our ambitious growth goals moving forward."

Mr. Long, a skillful financial executive with more than 25 years of experience with private healthcare technology and services companies, began his career at Price Waterhouse and Touche Ross Consulting. Most recently, he was Interim Chief Financial Officer at MDLIVE, a leading telehealth provider of virtual, on-demand healthcare delivery services that has experienced dramatic growth. Prior to MDLIVE, he held several key leadership positions at Empresario Partners (an interim management consultancy), Lakeview Health Systems, First Med, MEDai (a SaaS predictive analytics technology firm), and CoreSource.

"I am thrilled to join Notal Vision during this dynamic and exciting time in the company's history," said Jim Long. "This is a unique opportunity to align with an organization that is passionate and committed to making a real difference in the lives of patients with AMD, and I look forward to working with Quinton and his team of dedicated, talented employees. The Medicare-covered ForeseeHome® technology offers patients and physicians a revolutionary at-home means of detecting changes in vision related to neovascular AMD, often before the patient is aware of them visually. Notal Vision's focus on innovation and product development will continue to drive our leadership position within the novel and evolving home-based telemonitoring industry."

About Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is the leading cause of severe vision loss and blindness in adults over age 50. The early stage of the disease, known as dry AMD, causes damage to the part of the retina called the macula, which is responsible for detailed central vision tasks like reading, driving and facial recognition. Patients with dry AMD may progress to the wet form of AMD, in which blood vessels form and may leak fluid and blood onto the retina. Several studies indicate that early detection of warning signs of disease progression provides patients the best chance to start therapy and maintain good vision and a better quality of life.

About ForeseeHome® AMD Monitoring Program

ForeseeHome Monitoring uses a technology known as preferential hyperacuity perimetry (PHP) to detect pattern defects across 500 points in the central 14° of a patient's retina. Over 1 million tests have been performed using the ForeseeHome® device.  After taking a simple self-administered 3-minute test, results are automatically transferred to the Notal Vision monitoring center and are available to the patient's eye doctor through a secure website. When a statistically significant change is detected on a patient's test, Notal Vision sends a prompt to the doctor to schedule a follow up appointment. To learn more, visit

About Notal Vision™

Notal Vision was founded by two ophthalmologists, and is committed to providing the eye care community with innovative, home-based, technology solutions that support visual health in patients with AMD.  The company's ForeseeHome® device is the first FDA-cleared home telemonitoring device that detects and characterizes visual distortion in AMD patients as an aid to monitoring progression to choroidal neovascularization. To learn more, visit

Editor's Details

Mike Wood

Last updated on: 25/07/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.